A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2018
At a glance
- Drugs Daprodustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms ASCEND-NHQ
- Sponsors GlaxoSmithKline
- 13 Jul 2018 Planned End Date changed from 12 Nov 2020 to 5 Nov 2020.
- 13 Jul 2018 Planned primary completion date changed from 12 Nov 2020 to 5 Nov 2020.
- 19 Mar 2018 Status changed from not yet recruiting to recruiting.